APO RESEARCH · REPORT
Conjugate Vaccine
Vaccines are used to prevent diseases by invoking an immune response to an antigen, the foreign part of a bacteria or virus that the immune system recognizes. Conjugate vaccines combine a weak antigen with a strong antigen as a carrier so that the immune system has a stronger response to the weak antigen.
Product & engineering
Understand the product.
Vaccines are used to prevent diseases by invoking an immune response to an antigen, the foreign part of a bacteria or virus that the immune system recognizes. Conjugate vaccines combine a weak antigen with a strong antigen as a carrier so that the immune system has a stronger response to the weak antigen.
Selected research
Industry Research
Conjugate Vaccine Industry Research Report 2026
Market perspective
Vaccines are used to prevent diseases by invoking an immune response to an antigen, the foreign part of a bacteria or virus that the immune system recognizes. Conjugate vaccines combine a weak antigen with a strong antigen as a carrier so that the immune system has a stronger response to the weak antigen.
Market competition is intense. Pfizer, GSK, Sanofi, Merck, etc. are the leaders of the industry, and they hold key technologies and patents, with high-end customers. Top 5 manufacturers accounted for 86.11% market share in 2019.
Report Scope
Read the full market overview
This report quantifies the global Conjugate Vaccine market in terms of revenue (US$ million) and, where applicable, sales volume (Million Unit), using 2025 as the base year and providing annual historical and forecast data for 2021–2032.
It standardizes definitions of Types and Applications, harmonizes vendor attribution, and presents comparable time series by company, Type, Application, and region/country, including indicative price bands (US$/Million Unit) and concentration ratios (CR5/CR10).
The outputs are intended to support strategy development, budgeting, and performance benchmarking for brand owners, manufacturers, retailers, channel partners, and investors; data are structured with consistent units and fields to facilitate integration into internal FP&A and BI systems.
Key Companies & Market Share Insights
This section profiles leading manufacturers, combining 2021–2025 results with a 2026–2032 outlook. It reports revenue, market share, price bands, product and application mix, regional and channel mix, and key developments (M&A, capacity additions, certifications). It also provides global revenue, average price, and—where applicable—sales volume by manufacturer, and calculates CR5/CR10 and rank changes to support comparative benchmarking.
Conjugate Vaccine Market by Company
Pfizer
GSK
Sanofi
Merck
Walvax Biotechnology
Royal (Wuxi) Bio-Pharmaceutical
Bharat Biotech
Zhifei Biologic
Conjugate Vaccine Segment by Type
Hib Vaccine
Meningococcal Vaccine
Pneumococcal Vaccine
Others
Conjugate Vaccine Segment by End Users
Children
Adult
Conjugate Vaccine Segment by Region
North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Spain
Netherlands
Switzerland
Sweden
Poland
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Middle East & Africa
Egypt
South Africa
Israel
Türkiye
GCC Countries
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Conjugate Vaccine market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Conjugate Vaccine and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Conjugate Vaccine.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc.), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Detailed analysis of Conjugate Vaccine manufacturers competitive landscape, price, production and value market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product production/output, value, price, gross margin, product introduction, recent development, etc.
Chapter 5: Production/output, value of Conjugate Vaccine by region/country. It provides a quantitative analysis of the market size and development potential of each region in the next six years.
Chapter 6: Consumption of Conjugate Vaccine in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and production of each country in the world.
Chapter 7: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 8: Provides the analysis of various market segments by end users, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 11: The main points and conclusions of the report.
More report detail
Tables and figures
Scope & coverage.
Types
- Hib Vaccine
- Meningococcal Vaccine
- Pneumococcal Vaccine
- Others
Applications
- Children
- Adult
Companies covered
- Pfizer
- GSK
- Sanofi
- Merck
- Walvax Biotechnology
- Royal (Wuxi) Bio-Pharmaceutical
- Bharat Biotech
- Zhifei Biologic
Inside the report.
1 Preface
- 1.1 Scope of Report
- 1.2 Reasons for Doing This Study
- 1.3 Research Methodology
- 1.4 Research Process
- 1.5 Data Source
- 1.5.1 Secondary Sources
- 1.5.2 Primary Sources
2 Market Overview
- 2.1 Product Definition
- 2.2 Global Market Growth Prospects
- 2.2.1 Global Conjugate Vaccine Market Size (2021-2032)
- 2.2.2 Global Conjugate Vaccine Sales (2021-2032)
- 2.2.3 Global Conjugate Vaccine Market Average Price (2021-2032)
- 2.3 Conjugate Vaccine by Type
- 2.3.1 Market Value Comparison by Type (2021 VS 2025 VS 2032) & (US$ Million)
- 2.3.2 Hib Vaccine
- 2.3.3 Meningococcal Vaccine
- 2.3.4 Pneumococcal Vaccine
- 2.3.5 Others
- 2.4 Conjugate Vaccine by End Users
- 2.4.1 Market Value Comparison by End Users (2021 VS 2025 VS 2032)
- 2.4.2 Children
- 2.4.3 Adult
3 Market Competitive Landscape by Manufacturers
- 3.1 Global Conjugate Vaccine Market Competitive Situation by Manufacturers (2021 Versus 2025)
- 3.2 Global Conjugate Vaccine Sales (Million Unit) of Manufacturers (2021-2026)
- 3.3 Global Conjugate Vaccine Revenue of Manufacturers (2021-2026)
- 3.4 Global Conjugate Vaccine Average Price by Manufacturers (2021-2026)
- 3.5 Global Conjugate Vaccine Industry Ranking, 2024 VS 2025 VS 2026
- 3.6 Global Manufacturers of Conjugate Vaccine, Manufacturing Sites & Headquarters
- 3.7 Global Manufacturers of Conjugate Vaccine, Product Type & Application
- 3.8 Global Manufacturers of Conjugate Vaccine, Established Date
- 3.9 Global Conjugate Vaccine Market CR5 and HHI
- 3.10 Global Manufacturers Mergers & Acquisition
4 Manufacturers Profiled
- 4.1 Pfizer
- 4.1.1 Pfizer Company Information
- 4.1.2 Pfizer Business Overview
- 4.1.3 Pfizer Conjugate Vaccine Sales, Revenue and Gross Margin (2021-2026)
- 4.1.4 Pfizer Conjugate Vaccine Product Portfolio
- 4.1.5 Pfizer Recent Developments
- 4.2 GSK
- 4.2.1 GSK Company Information
- 4.2.2 GSK Business Overview
- 4.2.3 GSK Conjugate Vaccine Sales, Revenue and Gross Margin (2021-2026)
- 4.2.4 GSK Conjugate Vaccine Product Portfolio
- 4.2.5 GSK Recent Developments
- 4.3 Sanofi
- 4.3.1 Sanofi Company Information
- 4.3.2 Sanofi Business Overview
- 4.3.3 Sanofi Conjugate Vaccine Sales, Revenue and Gross Margin (2021-2026)
- 4.3.4 Sanofi Conjugate Vaccine Product Portfolio
- 4.3.5 Sanofi Recent Developments
- 4.4 Merck
- 4.4.1 Merck Company Information
- 4.4.2 Merck Business Overview
- 4.4.3 Merck Conjugate Vaccine Sales, Revenue and Gross Margin (2021-2026)
- 4.4.4 Merck Conjugate Vaccine Product Portfolio
- 4.4.5 Merck Recent Developments
- 4.5 Walvax Biotechnology
- 4.5.1 Walvax Biotechnology Company Information
- 4.5.2 Walvax Biotechnology Business Overview
- 4.5.3 Walvax Biotechnology Conjugate Vaccine Sales, Revenue and Gross Margin (2021-2026)
- 4.5.4 Walvax Biotechnology Conjugate Vaccine Product Portfolio
- 4.5.5 Walvax Biotechnology Recent Developments
- 4.6 Royal (Wuxi) Bio-Pharmaceutical
- 4.6.1 Royal (Wuxi) Bio-Pharmaceutical Company Information
- 4.6.2 Royal (Wuxi) Bio-Pharmaceutical Business Overview
- 4.6.3 Royal (Wuxi) Bio-Pharmaceutical Conjugate Vaccine Sales, Revenue and Gross Margin (2021-2026)
- 4.6.4 Royal (Wuxi) Bio-Pharmaceutical Conjugate Vaccine Product Portfolio
- 4.6.5 Royal (Wuxi) Bio-Pharmaceutical Recent Developments
- 4.7 Bharat Biotech
- 4.7.1 Bharat Biotech Company Information
- 4.7.2 Bharat Biotech Business Overview
- 4.7.3 Bharat Biotech Conjugate Vaccine Sales, Revenue and Gross Margin (2021-2026)
- 4.7.4 Bharat Biotech Conjugate Vaccine Product Portfolio
- 4.7.5 Bharat Biotech Recent Developments
- 4.8 Zhifei Biologic
- 4.8.1 Zhifei Biologic Company Information
- 4.8.2 Zhifei Biologic Business Overview
- 4.8.3 Zhifei Biologic Conjugate Vaccine Sales, Revenue and Gross Margin (2021-2026)
- 4.8.4 Zhifei Biologic Conjugate Vaccine Product Portfolio
- 4.8.5 Zhifei Biologic Recent Developments
5 Global Conjugate Vaccine Market Scenario by Region
- 5.1 Global Conjugate Vaccine Market Size by Region: 2021 VS 2025 VS 2032
- 5.2 Global Conjugate Vaccine Sales by Region: 2021-2032
- 5.2.1 Global Conjugate Vaccine Sales by Region: 2021-2026
- 5.2.2 Global Conjugate Vaccine Sales by Region: 2027-2032
- 5.3 Global Conjugate Vaccine Revenue by Region: 2021-2032
- 5.3.1 Global Conjugate Vaccine Revenue by Region: 2021-2026
- 5.3.2 Global Conjugate Vaccine Revenue by Region: 2027-2032
- 5.4 North America Conjugate Vaccine Market Facts & Figures by Country
- 5.4.1 North America Conjugate Vaccine Market Size by Country: 2021 VS 2025 VS 2032
- 5.4.2 North America Conjugate Vaccine Sales by Country (2021-2032)
- 5.4.3 North America Conjugate Vaccine Revenue by Country (2021-2032)
- 5.4.4 United States
- 5.4.5 Canada
- 5.4.6 Mexico
- 5.5 Europe Conjugate Vaccine Market Facts & Figures by Country
- 5.5.1 Europe Conjugate Vaccine Market Size by Country: 2021 VS 2025 VS 2032
- 5.5.2 Europe Conjugate Vaccine Sales by Country (2021-2032)
- 5.5.3 Europe Conjugate Vaccine Revenue by Country (2021-2032)
- 5.5.4 Germany
- 5.5.5 France
- 5.5.6 U.K.
- 5.5.7 Italy
- 5.5.8 Russia
- 5.5.9 Spain
- 5.5.10 Netherlands
- 5.5.11 Switzerland
- 5.5.12 Sweden
- 5.5.13 Poland
- 5.6 Asia Pacific Conjugate Vaccine Market Facts & Figures by Country
- 5.6.1 Asia Pacific Conjugate Vaccine Market Size by Country: 2021 VS 2025 VS 2032
- 5.6.2 Asia Pacific Conjugate Vaccine Sales by Country (2021-2032)
- 5.6.3 Asia Pacific Conjugate Vaccine Revenue by Country (2021-2032)
- 5.6.4 China
- 5.6.5 Japan
- 5.6.6 South Korea
- 5.6.7 India
- 5.6.8 Australia
- 5.6.9 Taiwan
- 5.6.10 Southeast Asia
- 5.7 South America Conjugate Vaccine Market Facts & Figures by Country
- 5.7.1 South America Conjugate Vaccine Market Size by Country: 2021 VS 2025 VS 2032
- 5.7.2 South America Conjugate Vaccine Sales by Country (2021-2032)
- 5.7.3 South America Conjugate Vaccine Revenue by Country (2021-2032)
- 5.7.4 Brazil
- 5.7.5 Argentina
- 5.7.6 Chile
- 5.8 Middle East and Africa Conjugate Vaccine Market Facts & Figures by Country
- 5.8.1 Middle East and Africa Conjugate Vaccine Market Size by Country: 2021 VS 2025 VS 2032
- 5.8.2 Middle East and Africa Conjugate Vaccine Sales by Country (2021-2032)
- 5.8.3 Middle East and Africa Conjugate Vaccine Revenue by Country (2021-2032)
- 5.8.4 Egypt
- 5.8.5 South Africa
- 5.8.6 Israel
- 5.8.7 Türkiye
- 5.8.8 GCC Countries
6 Segment by Type
- 6.1 Global Conjugate Vaccine Sales by Type (2021-2032)
- 6.1.1 Global Conjugate Vaccine Sales by Type (2021-2032) & (Million Unit)
- 6.1.2 Global Conjugate Vaccine Sales Market Share by Type (2021-2032)
- 6.2 Global Conjugate Vaccine Revenue by Type (2021-2032)
- 6.2.1 Global Conjugate Vaccine Sales by Type (2021-2032) & (US$ Million)
- 6.2.2 Global Conjugate Vaccine Revenue Market Share by Type (2021-2032)
- 6.3 Global Conjugate Vaccine Price by Type (2021-2032)
7 Segment by End Users
- 7.1 Global Conjugate Vaccine Sales by End Users (2021-2032)
- 7.1.1 Global Conjugate Vaccine Sales by End Users (2021-2032) & (Million Unit)
- 7.1.2 Global Conjugate Vaccine Sales Market Share by End Users (2021-2032)
- 7.2 Global Conjugate Vaccine Revenue by End Users (2021-2032)
- 7.2.1 Global Conjugate Vaccine Sales by End Users (2021-2032) & (US$ Million)
- 7.2.2 Global Conjugate Vaccine Revenue Market Share by End Users (2021-2032)
- 7.3 Global Conjugate Vaccine Price by End Users (2021-2032)
8 Value Chain and Sales Channels Analysis of the Market
- 8.1 Conjugate Vaccine Value Chain Analysis
- 8.1.1 Conjugate Vaccine Key Raw Materials
- 8.1.2 Raw Materials Key Suppliers
- 8.1.3 Conjugate Vaccine Production Mode & Process
- 8.2 Conjugate Vaccine Sales Channels Analysis
- 8.2.1 Direct Comparison with Distribution Share
- 8.2.2 Conjugate Vaccine Distributors
- 8.2.3 Conjugate Vaccine Customers
9 Global Conjugate Vaccine Analyzing Market Dynamics
- 9.1 Conjugate Vaccine Industry Trends
- 9.2 Conjugate Vaccine Industry Drivers
- 9.3 Conjugate Vaccine Industry Opportunities and Challenges
- 9.4 Conjugate Vaccine Industry Restraints
10 Report Conclusion
11 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst